Suppression of autoimmunity and renal disease in pristane-induced lupus by myeloperoxidase

Arthritis and Rheumatology

Volumn 67, Issue 7, 2015, Pages 1868-1880

  Odobasic, Dragana ^a   Muljadi, Ruth C M ^a   O'Sullivan, Kim M ^a   Kettle, Anthony J ^b   Dickerhof, Nina ^b   Summers, Shaun A ^c   Kitching, A Richard ^a   Holdsworth, Stephen R ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c Monash Health ^*

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; CYTOKINE; DNA; GLUTATHIONE DERIVATIVE; GLUTATHIONE SULFONAMIDE; IMMUNOGLOBULIN G; MYELOPEROXIDASE; OXIDIZED DNA; PRISTANE; SULFONAMIDE; UNCLASSIFIED DRUG; PEROXIDASE; TERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPOSITION; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; ENZYME ACTIVITY; EXTRACELLULAR TRAP; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS; IMMUNOLOGICAL PARAMETERS; IMMUNOPATHOGENESIS; KIDNEY INJURY; LEUKOCYTOCLASTIC VASCULITIS; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PERITONEAL CAVITY; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY VASCULITIS; T LYMPHOCYTE ACTIVATION; WILD TYPE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DEFICIENCY; DISEASE MODEL; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; KNOCKOUT MOUSE; LUPUS NEPHRITIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERITONEUM; PHYSIOLOGY;

ANIMALS; APOPTOSIS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRAPERITONEAL; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; PERITONEUM; PEROXIDASE; TERPENES;

EID: 84933074147     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39109     Document Type: Article

References (50)

1. Nowling TK, Gilkeson GS., Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011; 13: 250.
2. Schwartzman-Morris J, Putterman C., Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol 2012; 2012: 604892.
3. Gaipl US, Voll RE, Sheriff A, Franz S, Kalden JR, Herrmann M., Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 2005; 4: 189-94.
4. Mortensen ES, Fenton KA, Rekvig OP., Lupus nephritis: the central role of nucleosomes revealed. Am J Pathol 2008; 172: 275-83.
5. Jabs DA, Burek CL, Hu Q, Kuppers RC, Lee B, Prendergast RA., Anti-CD4 monoclonal antibody therapy suppresses autoimmune disease in MRL/Mp-lpr/lpr mice. Cell Immunol 1992; 141: 496-507.
6. Koh DR, Ho A, Rahemtulla A, Fung-Leung WP, Griesser H, Mak TW., Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur J Immunol 1995; 25: 2558-62.
7. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, Zidanic M, et al., Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J Immunol 2007; 178: 1938-47.
8. Saxena R, Mahajan T, Mohan C., Lupus nephritis: current update. Arthritis Res Ther 2011; 13: 240.
9. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, et al., Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187: 538-52.
10. Ocuin LM, Bamboat ZM, Balachandran VP, Cavnar MJ, Obaid H, Plitas G, et al., Neutrophil IL-10 suppresses peritoneal inflammatory monocytes during polymicrobial sepsis. J Leukoc Biol 2011; 89: 423-32.
11. Zehntner SP, Brickman C, Bourbonniere L, Remington L, Caruso M, Owens T., Neutrophils that infiltrate the central nervous system regulate T cell responses. J Immunol 2005; 174: 5124-31.
12. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al., A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012; 122: 327-36.
13. Calvani N, Caricchio R, Tucci M, Sobel ES, Silvestris F, Tartaglia P, et al., Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. J Immunol 2005; 175: 4777-82.
14. Lee PY, Weinstein JS, Nacionales DC, Scumpia PO, Li Y, Butfiloski E, et al., A novel type I IFN-producing cell subset in murine lupus. J Immunol 2008; 180: 5101-8.
15. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L., Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 2009; 30: 455-64.
16. Nacionales DC, Kelly-Scumpia KM, Lee PY, Weinstein JS, Lyons R, Sobel E, et al., Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum 2007; 56: 3770-83.
17. Richards HB, Satoh M, Jennette JC, Croker BP, Yoshida H, Reeves WH., Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. Kidney Int 2001; 60: 2173-80.
18. Summers SA, Odobasic D, Khouri MB, Steinmetz OM, Yang Y, Holdsworth SR, et al., Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. Clin Exp Immunol 2014; 176: 341-50.
19. Klebanoff SJ., Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77: 598-625.
20. Harwood DT, Kettle AJ, Brennan S, Winterbourn CC., Simultaneous determination of reduced glutathione, glutathione disulphide and glutathione sulphonamide in cells and physiological fluids by isotope dilution liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 3393-9.
21. Klebanoff SJ, Kettle AJ, Rosen H, Winterbourn CC, Nauseef WM., Myeloperoxidase: a front-line defender against phagocytosed microorganisms. J Leukoc Biol 2013; 93: 185-98.
22. Malle E, Buch T, Grone HJ., Myeloperoxidase in kidney disease. Kidney Int 2003; 64: 1956-67.
23. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 2000; 267: 4495-503.
24. Nussbaum C, Klinke A, Adam M, Baldus S, Sperandio M., Myeloperoxidase: a leukocyte-derived protagonist of inflammation and cardiovascular disease. Antioxid Redox Signal 2013; 18: 692-713.
25. Stamp LK, Khalilova I, Tarr JM, Senthilmohan R, Turner R, Haigh RC, et al., Myeloperoxidase and oxidative stress in rheumatoid arthritis. Rheumatology (Oxford) 2012; 51: 1796-803.
26. Metzler KD, Fuchs TA, Nauseef WM, Reumaux D, Roesler J, Schulze I, et al., Myeloperoxidase is required for neutrophil extracellular trap formation: implications for innate immunity. Blood 2011; 117: 953-9.
27. Brennan M, Gaur A, Pahuja A, Lusis AJ, Reynolds WF., Mice lacking myeloperoxidase are more susceptible to experimental autoimmune encephalomyelitis. J Neuroimmunol 2001; 112: 97-105.
28. Odobasic D, Kitching AR, Semple TJ, Holdsworth SR., Endogenous myeloperoxidase promotes neutrophil-mediated renal injury, but attenuates T cell immunity inducing crescentic glomerulonephritis. J Am Soc Nephrol 2007; 18: 760-70.
29. Odobasic D, Kitching AR, Yang Y, O'Sullivan KM, Muljadi RC, Edgtton KL, et al., Neutrophil myeloperoxidase regulates T-cell-driven tissue inflammation in mice by inhibiting dendritic cell function. Blood 2013; 121: 4195-204.
30. Bouali H, Nietert P, Nowling TM, Pandey J, Dooley MA, Cooper G, et al., Association of the G-463A myeloperoxidase gene polymorphism with renal disease in African Americans with systemic lupus erythematosus. J Rheumatol 2007; 34: 2028-34.
31. Brennan ML, Anderson MM, Shih DM, Qu XD, Wang X, Mehta AC, et al., Increased atherosclerosis in myeloperoxidase-deficient mice. J Clin Invest 2001; 107: 419-30.
32. Summers SA, Hoi A, Steinmetz OM, O'Sullivan KM, Ooi JD, Odobasic D, et al., TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun 2010; 35: 291-8.
33. Odobasic D, Gan PY, Summers SA, Semple TJ, Muljadi RC, Iwakura Y, et al., Interleukin-17A promotes early but attenuates established disease in crescentic glomerulonephritis in mice. Am J Pathol 2011; 179: 1188-98.
34. Hirahashi J, Hishikawa K, Kaname S, Tsuboi N, Wang Y, Simon DI, et al., Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation 2009; 120: 1255-65.
35. Odobasic D, Yang Y, Muljadi RC, O'Sullivan KM, Kao W, Smith M, et al., Endogenous myeloperoxidase is a mediator of joint inflammation and damage in experimental arthritis. Arthritis Rheumatol 2014; 66: 907-17.
36. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al., Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-5.
37. Jansson G., Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes: a possible cause of oxidative stress in inflammatory cells. Free Radic Res Commun 1991; 14: 195-208.
38. Perl A., Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 2013; 9: 674-86.
39. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al., Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010; 107: 9813-8.
40. Haas C, Ryffel B, Le Hir M., IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol 1997; 158: 5484-91.
41. Nasr SH, D'Agati VD, Park HR, Sterman PL, Goyzueta JD, Dressler RM, et al., Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity. Clin J Am Soc Nephrol 2008; 3: 682-90.
42. Barker TT, Lee PY, Kelly-Scumpia KM, Weinstein JS, Nacionales DC, Kumagai Y, et al., Pathogenic role of B cells in the development of diffuse alveolar hemorrhage induced by pristane. Lab Invest 2011; 91: 1540-50.
43. Kuligowski MP, Kitching AR, Hickey MJ., Leukocyte recruitment to the inflamed glomerulus: a critical role for platelet-derived P-selectin in the absence of rolling. J Immunol 2006; 176: 6991-9.
44. Calvani N, Satoh M, Croker BP, Reeves WH, Richards HB., Nephritogenic autoantibodies but absence of nephritis in IL-12p35-deficient mice with pristane-induced lupus. Kidney Int 2003; 64: 897-905.
45. Hoi AY, Hickey MJ, Hall P, Yamana J, O'Sullivan KM, Santos LL, et al., Macrophage migration inhibitory factor deficiency attenuates macrophage recruitment, glomerulonephritis, and lethality in MRL/lpr mice. J Immunol 2006; 177: 5687-96.
46. Campbell AM, Kashgarian M, Shlomchik MJ., NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci Transl Med 2012; 4: 157ra41.
47. Akong-Moore K, Chow OA, von Kockritz-Blickwede M, Nizet V., Influences of chloride and hypochlorite on neutrophil extracellular trap formation. PLoS One 2012; 7: e42984.
48. Parker H, Dragunow M, Hampton MB, Kettle AJ, Winterbourn CC., Requirements for NADPH oxidase and myeloperoxidase in neutrophil extracellular trap formation differ depending on the stimulus. J Leukoc Biol 2012; 92: 841-9.
49. El Kebir D, Jozsef L, Pan W, Filep JG., Myeloperoxidase delays neutrophil apoptosis through CD11b/CD18 integrins and prolongs inflammation. Circ Res 2008; 103: 352-9.
50. Clark RA, Szot S., Chemotactic factor inactivation by stimulated human neutrophils mediated by myeloperoxidase-catalyzed methionine oxidation. J Immunol 1982; 128: 1507-13.